Understanding genetic contributions to medication response will allow for the development of personalized treatment based on predicted individual neurotransmitter tone and risk of adverse drug events
IRVINE, CA (PRWEB) August 28, 2015
Proove Biosciences, a commercial and research leader in Personalized Medicine, presented two studies at the International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ASM event took place on July 28th, 2015 through to August 1st, 2015. With a focus on evidence-based research and clinical application, the event gathered industry thought leaders to discuss the future of pain management. Proove Biosciences contributed through the presentation of two new research studies: 1) Pain and Genetics: Study of Different Genes that are Prevalent in Different Pain Patients and 2) Genetics and Drug Response: Influence of Variations in ANKK1 and DBH in Individual Response to Oxycodone Medication (Among Patients with Spondylosis and Allied Disorders).
The Pain and Genetics: Study of Different Genes that are Prevalent in Different Pain Patients concerns the influence pain perception pathway genes may have in predisposing individuals to pain related health issues such as low back pain or limb pain. By analyzing the genetic information of pain patients diagnosed with a pain related health issue, Proove Biosciences’ researchers were able to assess the influence of genetics on the characterization and localization of pain disorders. Researchers found a significant association between pain disorders and the MTHFR and 5-HTTLPR genes. Results showed that certain genetic variations, namely the T/T and C/T variations of the MTHFR gene and the A/A and G/A variations of the 5-HTTPLR gene, were significantly more prevalent in pain patient with localized pain.
“This suggests that we may not only be able to predict the location and characterization of pain disorders, but also potentially develop new therapeutic approaches to treat common pain disease states based on neurochemical imbalances due to these genetic variations.” said Derrick Holman, MD, Clinical Science Liaison at Proove Biosciences
The Genetics and Drug Response: Influence of Variations in ANKK1 And DBH in Individual Response to Oxycodone Medication (Among Patients with Spondylosis and Allied Disorders) was conducted to determine the role of genetics in an individual’s response to oxycodone, with a particular focus on patients diagnosed with arthritis in the spine and the co-morbid disorders that go with it. By analyzing the genetic information of patients taking only oxycodone while diagnosed with spondylosis (arthritis in the spine), Proove Biosciences’ researchers found that certain genetic variations were associated with being a good or poor responder to Oxycodone. An analysis of the ANKK1 gene showed that, when compared to a combination of C/C-C/T genotypes, the T/T genotypic variation is more likely to be associated with good response to Oxycodone, while an analysis of the DBH gene showed that a T/T variation is more likely to be associated with poor Oxycodone response compared to a combination of C/C-C/T.
“The goal of these studies is to dissect the biology of drug response down to the single nucleotide level,” stated Dr. Holman. “Understanding genetic contributions to medication response will allow for the development of personalized treatment based on predicted individual neurotransmitter tone and risk of adverse drug events.”
About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832) or call toll free 855-PROOVE-BIO (855-776-6832).